These 5 Healthcare Penny Stocks Are Poised To Jump

4. Mast Therapeutics Inc (NYSEMKT:MSTX)

Investors with Long Positions (as of June 30): 7

Aggregate Value of Investors’ Holdings (as of June 30): $6.75 Million

So far this year, Mast Therapeutics’ stock has depreciated by nearly 17%, while ‘hedgies’ turned slightly bearish towards the company during the second trimester, as their total investments decreased by $2.23 million, although the total number of hedge funds invested in the company remained unchanged. The aggregate value of investors’ holdings represented 8.5% of Mast Therapeutics’ shares. The biopharmaceutical company’s lead candidate is vepoloxamer, a drug for sickle cell disease. In August, Mast Therapeutics Inc (NYSEMKT:MSTX)’s CEO Brian Culley revealed that the company has completed 70% of the enrollment process for its Phase 3 study called EPIC, which is aimed at showing that vepoloxamer can reduce the duration of vaso-occlusive crisis; top line data is expected in the first quarter of 2016. Biotechnology Value Fund, managed by Mark Lampert, heads our list of Mast Therapeutics Inc (NYSEMKT:MSTX)’s shareholders, as it owns about 5.11 million shares valued at $2.51 million.